Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeluvalimab in advanced solid tumors
NCT03853109Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2019
- Primary completion
- Jul 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 1, open-label trial of zeluvalimab in solid tumor (advanced stage) (8 cohorts), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced Dose Limiting Toxicities and Number of Participants Who Experienced Treatment-emergent Adverse Events up to 46 months. Started Mar 2019; status: completed.
02
Drugs
zeluvalimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03853109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853109.